2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析

doi:10.11904/j.issn.1002-3070.2023.04.001

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (4): 293-300.doi: 10.11904/j.issn.1002-3070.2023.04.001

• 癌情监测 • 下一篇

2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析

文洪梅¹, 陈杨¹, 石青萍¹, 朱云芳¹, 任思颖¹, 唐娴¹, 邵英¹, 伍福仙¹, 李云飞²

1.云南省疾病预防控制中心慢性非传染性疾病防制所(昆明 650022);
2.昆明医科大学第二附属医院脑血管病科

收稿日期:2023-06-09 修回日期:2023-09-21 出版日期:2023-08-28 发布日期:2023-12-12
通讯作者: 李云飞,E-mail:yunfeili2009@126.com
作者简介:文洪梅,女,(1986-),硕士,主管医师,从事肿瘤及慢性病监测评价的研究。
基金资助:
中国医学科学院医学与科技创新工程重大协同创新项目(编号:2021-I2M-1-011)

Analysis of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2018

WEN Hongmei¹, CHEN Yang¹, SHI Qingping¹, ZHU Yunfang¹, REN Siying¹, TANG Xian¹, SHAO Ying¹, WU Fuxian¹, LI Yunfei²

1. Institute for the Prevention and Control of Chronic non-Communicable Diseases of Yunnan Provincial Center for Disease Control and Prevention, Kunming 650022, China;
2. Department of Cerebrovascular Disease, The Second Affiliated Hospital of Kunming Medical University

Received:2023-06-09 Revised:2023-09-21 Online:2023-08-28 Published:2023-12-12

摘要/Abstract

摘要： 目的分析2018年云南省肿瘤登记地区恶性肿瘤发病与死亡情况。方法收集云南省46个肿瘤登记地区2018年恶性肿瘤发病、死亡以及人口资料,按照地区、性别、年龄组分层,统计分析恶性肿瘤发病(死亡)率、发病(死亡)标化率、0~74岁累积率以及前10位恶性肿瘤发病和死亡顺位及构成。其中分别采用2000年全国普查标准人口年龄结构、Segi′s世界标准人口年龄结构进行标化率的计算。结果 2018年云南省肿瘤登记地区恶性肿瘤粗发病率为214.84/10万,中标发病率为155.99/10万,世标发病率为167.30/10万。年龄别发病率在45岁以前处于较低水平,45岁后快速上升,在80~84岁达到发病高峰,主要恶性肿瘤发病顺位依次为肺癌、女性乳腺癌、结直肠癌、肝癌和子宫颈癌。云南省肿瘤登记地区2018年恶性肿瘤的粗死亡率为128.63/10万,中标死亡率为88.50/10万,世标死亡率为98.78/10万,恶性肿瘤死亡率在45岁以前处于较低水平,45岁后快速上升,在85+岁达到死亡高峰,男性各年龄组死亡率均高于女性。主要恶性肿瘤死亡顺位依次为肺癌、肝癌、结直肠癌、胃癌和女性乳腺癌。前列腺癌的发病率高于全国西部地区水平,食管癌的发病率低于全国西部地区水平。结论云南省肿瘤登记地区恶性肿瘤的发病水平低于全国西部地区水平,肺癌、女性乳腺癌、结直肠癌、肝癌和子宫颈癌是需要重点防治的癌种,前列腺癌和食管癌的发病具有本地特征。

关键词: 肿瘤登记, 恶性肿瘤, 发病率, 死亡率, 云南

Abstract: Objective The objective of this study was to analyze the incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2018. Methods The data on the incidence, death, and population of malignant tumors in 46 cancer registration areas in Yunnan province in 2018 were collected. The incidence, mortality, age-standardized incidence and mortality, the cumulative rate from 0 to 74 years old, as well as ranking and composition of the top 10 malignant tumor incidence and mortality were analyzed, and stratified by region, gender and age. The standardized rates were calculated using the China 2000 national census standard population age structure and Segi′s world standard population age structure, respectively. Results In 2018, the crude incidence of malignant tumors was 214.84/100,000 in tumor registration areas of Yunnan province, and China age-standardized rate was 155.99/100,000 and world age-standardized rate was 167.30/100,000. The age specific incidence was at a low level before the age of 45, and rose rapidly after the age of 45. It reached its peak at the age of 80 to 84. The main malignant tumors were lung cancer, female breast cancer, colorectal cancer, liver cancer, and cervix cancer. The crude mortality of malignant tumors was 128.63/100,000 in the cancer registration areas of Yunnan province in 2018, the China and world age standardized rates were 88.50/100,000 and 98.78/100,000, respectively. The mortality of malignant tumors was at a relatively low level before the age of 45, rapidly increasing after the age of 45, reaching the peak of death at the age of 85+. The mortality of all age groups in males was higher than that in females. The main malignant tumors were lung cancer, liver cancer, colorectal cancer, stomach cancer and female breast cancer in the order of death. The incidence of prostate cancer was higher than that of Western China, and the incidence of esophageal cancer was lower than that of Western China. Conclusion The incidence of malignant tumors in cancer registration areas in Yunnan province is lower than that in Western China. Lung cancer, female breast cancer, colorectal cancer, liver cancer and cervical cancer are the cancers that need to be focused on prevention and treatment. The incidence of prostate cancer and esophageal cancer has local characteristics.

Key words: Cancer registration, Malignant tumor, Incidence, Mortality, Yunnan

中图分类号:

R736.1

文洪梅, 陈杨, 石青萍, 朱云芳, 任思颖, 唐娴, 邵英, 伍福仙, 李云飞. 2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(4): 293-300.

WEN Hongmei, CHEN Yang, SHI Qingping, ZHU Yunfang, REN Siying, TANG Xian, SHAO Ying, WU Fuxian, LI Yunfei. Analysis of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2018[J]. Journal of Practical Oncology, 2023, 37(4): 293-300.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.04.001

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I4/293

参考文献

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 文洪梅,秦明芳,陈杨,等.2014年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J].中国肿瘤,2018,27(11):813-823.
3 文洪梅,陈杨,王建宁,等.2013年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析[J].中国肿瘤,2018,27(1):23-30.
4 文洪梅,成会荣,王建宁,等.2011年云南省肿瘤登记地区恶性肿瘤的发病与死亡[J].中国肿瘤,2016,25(8):579-588.
5 文洪梅,任思颖,王建宁,等.云南省肿瘤登记地区2012年恶性肿瘤的发病与死亡分析[J].中国肿瘤,2016,25(12):950-956.
6 文洪梅,陈杨,石青萍,等.2016年云南省肿瘤登记地区恶性肿瘤的发病和死亡分析[J].实用肿瘤学杂志,2020,170(6):485-490.
7 文洪梅,高娇,陈杨,等.2015年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J].中国肿瘤,2020,29(1):22-33.
8 Bray F,Parkin DM.Evaluation of data quality in the cancer registry:principles and methods.PartⅠ:comparability,validity and timeliness[J].Eur J Cancer,2009,45(5):747-755.
9 国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016:1-482.
10 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
11 国家癌症中心.2020中国肿瘤登记年报[M].北京:人民卫生出版社,2012:70-80.
12 Rebbeck TR,Devesa SS,Chang BL,et al.Global patterns of prostate cancer incidence,aggressiveness,and mortality in men of African descent[J].Prostate Cancer,2013:560857.
13 Marmot M.Food,nutrition,physical activity,and the prevention of cancer[R].Washington,DC:American Institute for Cancer Research,2009:305-340.
14 Zhou CK,Check DP,Lortet-Tieulent J,et al.Prostate cancer incidence in 43 populations worldwide:an analysis of time trends overall and by age group[J].Int J Cancer,2016,138:1388-1400.
15 Center MM,Jemal A,Lortet-Tieulent J,et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol,2012,61(6):1079-1092.
16 Kvale R,Auvinen A,Adami HO,et al.Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries[J].J Natl Cancer Inst,2007,99(24):1881-1887.
17 R Chou,JM Croswell,T Dana,et al.Screening for prostate cancer:U.S.Preventive Services Task Force recommendation statement[J].Ann Intern Med,2008,149(3):185-191.
18 Moyer VA.Screening for prostate cancer:U.S.preventive services task force recommendation statement[J].Ann Intern Med,2012,157(2):120-134.
19 Tikkinen KAO,Dahm P,Lytvyn L,et al.Prostate cancer screening with prostate-specific antigen(PSA)test:a clinical practice guideline[J].BMJ,2018,362:k3581.
20 Zargar H,van den Bergh R,Moon D,et al.The impact of the United States Preventive Services Task Force(USPTSTF)recommendations against prostate-specific antigen(PSA)testing on PSA testing in Australia[J].BJU Int,2017,119(1):110-115.
21 Bray F,Pineros M.Cancer patterns,trends and projections in Latin America and the Caribbean:a global context[J].Salud Publica Mex,2016,58(2):104-117.
22 Seraphin TP,Joko-Fru WY,Kamate B,et al.Rising prostate cancer incidence in sub-Saharan Africa:a trend analysis of data from the African Cancer Registry Network[R].Cancer Epidemiol Biomarkers Prev,2020:8-10.
23 Ferlay J,Ervik M,Lam F,et al.Global cancer observatory:Cancer today[R].International Agency for Research on Cancer,2020:11-25.
24 Arnold M,Abnet CC,Neale RE,et al.Global burden of 5 major types of gastrointestinal cancer[J].Gastroenterology,2020,159(1):335-349.
25 Thun M,Linet MS,Cerhan JR,et al.Cancer epidemiology and prevention[M].Oxford University Press,2018:579-593.
26 Arnold M,Laversanne M,Brown LM,et al.Predicting the future burden of esophageal cancer by histological subtype:international trends in incidence up to 2030[J].Am J Gastroenterol,2017,112(8):1247-1255.

[1]	马晶昱, 相智声, 林永添, 温烨莹, 周衍. 2011—2020年福建省肿瘤登记地区甲状腺癌流行特征及变化趋势[J]. 实用肿瘤学杂志, 2023, 37(4): 301-307.
[2]	高哲敏, 李晓雪, 霍恺, 王立彬, 陈静, 鲁文慧. 沧州市区2010—2019年甲状腺癌发病时间趋势和生存分析[J]. 实用肿瘤学杂志, 2023, 37(3): 195-199.
[3]	王晶, 杜婧, 苏健婷, 刘庆萍, 王苹, 韦再华. 1990—2019年北京市食管癌死亡趋势年龄时期队列模型分析[J]. 实用肿瘤学杂志, 2023, 37(2): 97-101.
[4]	周海茸, 王巍巍, 王琛琛, 洪忻. 2007—2019年南京市胃癌死亡率及早死寿命损失年变化趋势分析[J]. 实用肿瘤学杂志, 2023, 37(2): 102-106.
[5]	杨建华, 罗赛美, 龙欣甜, 李蔚, 杨璧榕, 余龙涛, 张腾, 文洪梅. 2017年云南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 6-10.
[6]	马骥雄, 马菊红, 周红, 鲁朝霞, 丁高恒, 刘玉琴. 2018年甘肃省白银市恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2023, 37(1): 11-16.
[7]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[8]	何晓晴, 柯鹏, 张新友. BCL-2抑制剂在血液恶性肿瘤中的靶向治疗应用及作用机制[J]. 实用肿瘤学杂志, 2022, 36(5): 452-457.
[9]	刘春勋, 王鹏, 赵浩然, 张玉宝. 基于年龄-时期-队列模型分析1990—2019年中国胆道癌死亡趋势的研究[J]. 实用肿瘤学杂志, 2022, 36(4): 299-303.
[10]	李鑫林, 周金意, 韩仁强, 蔡波, 徐红, 韩颖颖. 2013—2017年南通市肺癌流行病学特征分析[J]. 实用肿瘤学杂志, 2022, 36(4): 304-309.
[11]	赵梓楠, 王国年. SOX4在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 364-368.
[12]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[13]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[14]	王艳平, 邱琳, 武萌, 飒日娜. 2016年陕西省恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2022, 36(1): 1-6.
[15]	刘芮, 陈杨, 石青萍, 余秋丽, 朱云芳, 文洪梅. 云南省肿瘤登记地区2012—2016年甲状腺癌发病与死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(6): 489-494.

2018年云南省肿瘤登记地区恶性肿瘤的发病与死亡分析

Analysis of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2018

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价